BMA
Banco Macro S.A.
There isn't enough reported data to score BMA yet.
IREN
IREN Limited
There isn't enough reported data to score IREN yet.
BMA Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Stable | |
| N/A | |
| N/A |
BMA's profitability is currently stable. There isn't enough data to rate its revenue. Free cash flow and net leverage aren't meaningful measures for financial services companies like BMA.
IREN Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Weak | |
| N/A | |
| N/A |
IREN's revenue and profitability are currently under pressure. Free cash flow and net leverage aren't meaningful measures for financial services companies like IREN.
BMA PE Valuation
BMA has no meaningful PE right now: it lost money over the past year.
IREN PE Valuation
IREN has no meaningful PE right now: it lost money over the past year.
BMA Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| High |
BMA has the edge over IREN on the outlook, with more favorable earnings expectations.
IREN Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses growing | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Low |
Analysts expect IREN's losses to grow, with revenue growing. However, they disagree widely on these estimates.
BMA Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2025 | $2.98 | -59% |
| Q2 2025 | $4.23 | -35% |
| Q1 2025 | -$0.48 | -104% |
| Q4 2024 | $3.45 | -51% |
| Q3 2024 | $7.21 | +226% |
| Q2 2024 | $6.52 | +198% |
| Q1 2024 | $11.38 | +1735% |
| Q4 2023 | $7.10 | +1009% |
BMA has the stronger earnings trend. Trailing diluted EPS is down 59% for BMA versus IREN down 347%.
IREN Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$3.96 | -347% |
| Q2 2026 | -$2.22 | -988% |
| Q1 2026 | $0.51 | +$1.10 |
| Q4 2025 | $1.18 | +$1.62 |
| Q3 2025 | $1.60 | +$1.99 |
| Q2 2025 | $0.25 | +$0.45 |
| Q1 2025 | -$0.59 | -$0.43 |
| Q4 2024 | -$0.44 | -$0.15 |
IREN has swung to a loss: it lost $3.96 per share over the past year, after a profit the year before.
BMA Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $950.1M | +4.1% |
| Q1 2026 | $1.2B | +70% |
| Q3 2025 | $933.9M | +30% |
| Q2 2025 | $912.7M | +16% |
| Q1 2025 | $725M | -66% |
| Q4 2024 | $970.7M | -44% |
| Q3 2024 | $719.9M | -46% |
| Q2 2024 | $789.5M | -29% |
BMA has the stronger quarterly revenue trend. Revenue is up 31% for BMA versus down 5.1% for IREN.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 22% | +15 points |
| Q1 2026 | 11% | -0.1 points |
| Q3 2025 | -2.6% | -14 points |
| Q2 2025 | 17% | +59 points |
| Q1 2025 | 7.2% | -10 points |
| Q4 2024 | 11% | -17 points |
| Q3 2024 | 11% | +8 points |
| Q2 2024 | -41% | -55 points |
BMA has the edge over IREN on profitability, with a higher operating margin.
IREN Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $228M | -5.1% |
| Q2 2026 | $137.2M | -27% |
| Q1 2026 | $144.8M | 0% |
| Q4 2025 | $184.7M | +59% |
| Q3 2025 | $240.3M | +355% |
| Q2 2025 | $187.3M | +230% |
| Q1 2025 | $144.8M | +168% |
| Q4 2024 | $116.1M | +176% |
IREN's revenue has held roughly level: $228M last quarter, down 5.1% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -82% | -50 points |
| Q2 2026 | -452% | -461 points |
| Q1 2026 | -161% | -180 points |
| Q4 2025 | -63% | -79 points |
| Q3 2025 | -32% | +57 points |
| Q2 2025 | 9% | +49 points |
| Q1 2025 | 19% | +8 points |
| Q4 2024 | 15% | +21 points |
IREN's operating margin was −82% last quarter, down 50 points from the same quarter a year ago.
BMA Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $372.3M | +$984.4M |
| Q1 2026 | $384.5M | +$1B |
| Q3 2025 | $304.5M | -63% |
| Q2 2025 | -$612.1M | -271% |
| Q1 2025 | -$616.8M | -10886964% |
| Q4 2024 | -$353.2M | -$232.5M |
| Q3 2024 | $818.8M | +$896.2M |
| Q2 2024 | $357M | +$365.4M |
BMA has the stronger cash trend. Its trailing FCF is up 207% versus its history, compared with IREN at down 479%.
IREN Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.6B | -$1.6B |
| Q2 2026 | $482.2M | +2895% |
| Q1 2026 | -$873.8M | -$523.1M |
| Q4 2025 | -$468M | -$334M |
| Q3 2025 | -$38M | +$349.4M |
| Q2 2025 | $16.1M | +$179M |
| Q1 2025 | -$350.7M | -$128.7M |
| Q4 2024 | -$134M | -$105.2M |
IREN's free cash flow was −$2.5B over the past year, against −$507M the year before. Free cash flow isn't a meaningful measure for financial services companies like IREN.
BMA Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.1% | -38K shares |
| 1 year | -0.1% | -40.3K shares |
| 3 years | -0.1% | -40.3K shares |
| 5 years | -1.2% | -804K shares |
| Available history | -0.1% | -38.8K shares |
BMA has the edge over IREN on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q2 2026 | — |
| Q1 2026 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | — |
| Q3 2024 | — |
| Q2 2024 | — |
IREN Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +26% | +82.4M shares |
| 1 year | +10% | +36.9M shares |
| 3 years | +511% | +333M shares |
| 5 years | +624% | +344M shares |
| Available history | +2346% | +382M shares |
IREN has 399M diluted shares, up 10% from a year ago.
| Quarter | Spent |
|---|---|
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | — |
| Q3 2024 | — |
| Q2 2024 | — |
| Q1 2024 | — |
| Q4 2023 | — |
| Q3 2023 | — |
BMA Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2025 | -3.1x | Net Cash |
| Q2 2025 | -2.0x | Net Cash |
| Q1 2025 | -57.5x | Net Cash |
| Q4 2024 | -4.4x | Net Cash |
| Q3 2024 | -2.8x | Net Cash |
| Q2 2024 | -1.3x | Net Cash |
| Q1 2024 | -0.4x | Net Cash |
| Q4 2023 | -1.5x | Net Cash |
BMA has more cash than debt. Net leverage isn't a meaningful measure for financial services companies like BMA.
IREN Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | 157.6x | High |
| Q4 2025 | 22.2x | High |
| Q3 2025 | 4.1x | High |
| Q2 2025 | 2.0x | Moderate |
| Q1 2025 | 3.3x | Elevated |
| Q4 2024 | -4.6x | Net Cash |
| Q3 2024 | -16.7x | Net Cash |
| Q2 2024 | -15.9x | Net Cash |
IREN's net debt is more than 20 years of its operating earnings (EBITDA), up from 3.3 years a year ago. Net leverage isn't a meaningful measure for financial services companies like IREN.
BMA Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 32.6 | Neutral |
| Stochastic | 4.0 | Oversold |
BMA's weekly RSI is 33 (neutral) and its Stochastic is 4 (oversold).
IREN Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 33.3 | Neutral |
| Stochastic | 8.2 | Oversold |
IREN's weekly RSI is 33 (neutral) and its Stochastic is 8 (oversold).
BMA PE vs Financial Services Sector
BMA has no meaningful PE right now: it lost money over the past year.
IREN PE vs Financial Services Sector
| Metric | IREN | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 13x | — |
IREN has no meaningful PE right now: it lost money over the past year.
BMA Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $62.7 | 12% below |
| 20 week MA | $75.0 | 26% below |
| 50 week MA | $80.5 | 31% below |
| 100 week MA | $79.3 | 30% below |
| 200 week MA | $59.4 | 6.9% below |
BMA is in a downtrend: it's below all five of its weekly moving averages, and 6.9% below its 200-week average.
IREN Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $29.8 | 35% below |
| 20 week MA | $36.2 | 46% below |
| 50 week MA | $42.8 | 54% below |
| 100 week MA | $32.0 | 39% below |
| 200 week MA | $19.1 | 2.1% above |
IREN has the edge over BMA on trend strength, trading above more of its moving averages.
BMA Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $36.4 | $15.6 | -57% |
| 2021 | $15.6 | $14.6 | -6.6% |
| 2022 | $14.6 | $15.8 | +8.9% |
| 2023 | $15.8 | $28.7 | +81% |
| 2024 | $28.7 | $100.2 | +249% |
| 2025 | $100.2 | $91.4 | -8.8% |
| 2026 YTD | $91.4 | $55.2 | -40% |
BMA has the edge over IREN on returns for 2026, with the stronger performance.
IREN Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $24.8 | $17.2 | -31% |
| 2022 | $17.2 | $1.19 | -93% |
| 2023 | $1.19 | $7.15 | +501% |
| 2024 | $7.15 | $10.7 | +50% |
| 2025 | $10.7 | $40.3 | +276% |
| 2026 YTD | $40.3 | $19.5 | -52% |
IREN's yearly returns have swung widely, from +501% in 2023 to −93% in 2022. It's down 52% so far in 2026.